Featured Research

from universities, journals, and other organizations

New Drug Effective For Rheumatoid Arthritis, Stanford Scientist Finds

Date:
September 15, 2005
Source:
Stanford University Medical Center
Summary:
A new drug appears to offer pain relief and increased mobility to rheumatoid arthritis patients who have exhausted their other medical treatment options. A researcher at the Stanford University School of Medicine led a six-month, multicenter clinical trial that found patients were more than twice as likely to have significant improvement with the new drug than with standard therapy.

STANFORD, Calif. -- A new drug appears to offer pain relief andincreased mobility to rheumatoid arthritis patients who have exhaustedtheir other medical treatment options. A researcher at the StanfordUniversity School of Medicine led a six-month, multicenter clinicaltrial that found patients were more than twice as likely to havesignificant improvement with the new drug than with standard therapy.The findings are reported in the Sept. 15 issue of the New EnglandJournal of Medicine.

The study was a phase-III trial, the final stage of human testingnormally required by the U.S. Food and Drug Administration before itwill consider approving a drug. Based on the results, an FDA advisorypanel met on Sept. 6 and recommended the drug's approval for thetreatment of rheumatoid arthritis in cases in which standard therapyhas failed.

Abatacept, marketed as Orencia, is made by Bristol-MyersSquibb, which sponsored the study. The lead author, Mark Genovese, MD,Stanford associate professor of medicine (immunology and rheumatology),is a paid consultant for the company.

"This drug works where others haven't," said Genovese, who isalso the associate chief of the medical school's Division of Immunologyand Rheumatology. "These patients had tried and failed the besttherapies to date, and they could still have a very good response tothis drug."

Autoimmune diseases such as rheumatoid arthritis arecharacterized by an overactive immune system that turns its attack tobody tissues instead of invading microbes. T cells are immune cellsthought to play a major role in the development of rheumatoidarthritis. Abatacept is the first of a class of drugs, calledco-stimulation blockers, that selectively impede one of the two signalsneeded to activate T cells.

"It's exciting to have a therapy with a new mechanism ofaction," said Genovese. "In the next few years we are going to get anincreasing sense of who the best patients are for this therapy and evenwhether patients with other autoimmune diseases might benefit."Bristol-Myers Squibb is also testing the drug for use in lupus.

Stuart Levine, MD, assistant professor of medicine in thedivision of rheumatology at Johns Hopkins University School ofMedicine, expressed optimism about the new drug. "This would likely bea useful addition to our armamentarium for patients who are failing orhave failed first-line therapy," said Levine, who has no financialconnections with Bristol-Myers Squibb and was not part of the study.

Rheumatoid arthritis is a disease of the joints that affectsmore than 2 million Americans. The disease is characterized by aninfiltration of the joints with immune cells aimed against the cellslining the joint. The immune system attack causes pain, stiffness andswelling of the joints and can eventually lead to cartilage breakdown,bone loss and weakness of the joints. Without effective therapy,approximately 15 percent of patients will be crippled by theirdisfigured joints.

Nonsteroidal anti-inflammatory drugs can provide pain relieffor rheumatoid arthritis but do not treat the underlying disease.Standard therapy currently includes other agents that suppress theimmune system and can actually modify the course of disease. Inaddition, new medications that block the immune system's response havebecome available in recent years. Still, many patients don't benefitfrom these medications.

Bristol-Myers Squibb conferred with Genovese and others todesign an international trial to test whether abatacept could benefitthese rheumatoid arthritis sufferers who hadn't responded to existingtherapy. At 89 sites around the world, 258 of these patients receivedabatacept as an intravenous injection seven times over the course ofthe study, and 133 patients received a placebo. Neither the patientsnor the physicians knew who received active drug.

After six months of treatment, half of the patients takingabatacept achieved at least 20 percent improvement compared with one ofevery five taking the placebo. The FDA requires that a majority ofpatients benefit by this degree before a drug can be approved fortreating rheumatoid arthritis.

A 20 percent improvement means a lot, Genovese said,particularly for the severely affected patients in this study, who hadan average of 30 tender joints each. "For many of these patients, itmeans a significant increase in their ability to function," he said."That means turning on the shower, opening a car door, using the toilet-- little actions that make a huge change in their quality of life."

One in five patients taking abatacept achieved at least 50percent improvement and one in 10 achieved the definition for remission-- a difficult hurdle to clear for a group that failed to seesignificant improvement from all other therapies.

According to the trial results, abatacept appears to be safe,with few side effects. About 2 percent of both groups experiencedserious infections. Mild to moderate infections such as bronchitis andupper respiratory tract infections were slightly higher in the grouptaking the drug -- 38 percent compared with 32 percent in the placebogroup.

"It"s a fine line between trying to modulate the immune systemand suppressing it to an extent that you are at an increased risk forinfections," said Genovese. The higher risk of less serious infectionsis something to keep in mind with abatacept.

"Any time you modulate the immune system you are at a potentialrisk," he said, "but you just have carefully weigh the risks and thebenefits."

###

Stanford University Medical Center integrates research, medicaleducation and patient care at its three institutions -- StanfordUniversity School of Medicine, Stanford Hospital & Clinics andLucile Packard Children's Hospital at Stanford. For more information,please visit the Web site of the medical center's Office ofCommunication & Public Affairs at http://mednews.stanford.edu.


Story Source:

The above story is based on materials provided by Stanford University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Stanford University Medical Center. "New Drug Effective For Rheumatoid Arthritis, Stanford Scientist Finds." ScienceDaily. ScienceDaily, 15 September 2005. <www.sciencedaily.com/releases/2005/09/050915010712.htm>.
Stanford University Medical Center. (2005, September 15). New Drug Effective For Rheumatoid Arthritis, Stanford Scientist Finds. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2005/09/050915010712.htm
Stanford University Medical Center. "New Drug Effective For Rheumatoid Arthritis, Stanford Scientist Finds." ScienceDaily. www.sciencedaily.com/releases/2005/09/050915010712.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins